News | April 27, 2024
AstraZeneca 1Q 2024 revenue up 19% to US$ 12,679 million
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
The company plans to add 1700 beds by FY27 through the organic route
Pharma Solutions operates 10 research and development and/or production sites globally
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
The company recently received CEP certificate approval for Losartan Potassium by EDQM
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency
The company reported lifetime high EBIDTA of Rs. 250 crores
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
